Maureen Ladouceur
Operating Partner, Healthcare Team at Welsh, Carson, Anderson & Stowe
Greater Philadelphia, PA
Now EnableComp's CCO after leaving WCAS in mid-2026, she brings rare RCM and payor commercial-scaling expertise from growing Norstella's revenue 30x.
Background
Maureen Ladouceur is a healthcare and life sciences commercial executive who began her career as a clinical registered nurse at Thomas Jefferson University Hospital before moving into commercial leadership roles at McKesson, Vocollect Healthcare Systems, and Quantia. She spent roughly a decade at MMIT/Norstella, rising to President and Global Chief Commercial Officer and growing revenue more than 30x through organic growth and integration of acquisitions including Citeline, Evaluate, MMIT, Panalgo, and The Dedham Group. She joined Welsh, Carson, Anderson & Stowe as an Operating Partner on the Healthcare Team in September 2025, then departed to become Chief Commercial Officer at EnableComp in June 2026.
Notable deals
- 2025
- 2025
- 2026
Call-prep brief
Background
- Started as a clinical RN at Thomas Jefferson University Hospital, then moved through commercial roles at McKesson, Vocollect Healthcare Systems, and Quantia.
- Spent roughly a decade at MMIT/Norstella (CRO → CCO → EVP & Global CCO/President), growing revenue 30x+ via organic growth and integrating five-plus acquisitions.
- BSN (Pitt), MBA (Penn State), business strategy certificate (Cornell).
Current focus
- CCO at EnableComp (since June 2026), leading commercial strategy for complex healthcare revenue-cycle management (RCM).
- Prior to that: Operating Partner, Healthcare Team at Welsh, Carson, Anderson & Stowe (Sept 2025–mid-2026) — a brief, ~9-month tenure.
What she cares about
- Translating clinical empathy (her nursing background) into commercial relationship-building.
- Scaling multi-business commercial organizations through M&A integration.
- Patient access to therapy across payor, provider, and life-sciences segments.
Sensitivities
- She is no longer at WCAS — outreach framed as "WCAS Operating Partner" is stale; approach her as an independent commercial-scaling expert, not a WCAS resource.
- Understand why the operating-partner seat was short-lived before assuming she wants portfolio-wide advisory work again.
- A previously reported AssistRx board seat could not be independently confirmed via public sources — verify directly before referencing it.
Questions to ask
- What made the full-time CCO seat at EnableComp a better fit than the WCAS operating-partner model, and what does that suggest about structuring operating talent at PE-backed healthcare platforms?
- Which specific commercial-integration playbooks from the Norstella/MMIT roll-up would translate to physician practice consolidation?
- Given her current RCM focus, what commercial or billing pitfalls should a physician-practice rollup diligence before close?
Outreach draft
Linked companies
Sources
- Page titleOtherenablecomp.com/news/enablecomp-names-maureen-ladouceur-chief-commercial-officer-to-accelerate-growth
- Bare nameOthernorstella.com/how-women-are-transforming-life-sciences
- Page titlePressprnewswire.com/news-releases/welsh-carson-anderson--stowe-welcomes-maureen-ladouceur-as-an-operating-partner-302570054.html